Drugs / LUTETIUM TEZUVOTIDEXETAN
LUTETIUM TEZUVOTIDEXETAN
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06516510 | Oct 2024 → Aug 2025 | metastatic prostate carcinoma | Blue Earth Therapeutics Ltd | Terminated | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT06105918 | Nov 2023 → Apr 2028 expected | prostate adenocarcinoma | Emory University | Active not recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06066437 | Mar 2024 → Dec 2026 expected | prostate cancer | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05413850 | Jul 2022 → Aug 2026 overdue | castration-resistant prostate carcinoma | Blue Earth Therapeutics Ltd | Recruiting | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LUTETIUM TEZUVOTIDEXETAN | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068768 ↗ |
| Known as | 177Lu rhPSMA-10.1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06066437 ↗ |
| Known as | Luteci0 (177lu) tezuvotida tetraxetan | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068768 ↗ |
| Known as | Lutecium (177lu) tezuvotide tetraxetan | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068768 ↗ |
| Known as | Lutetium (177Lu) rhPSMA-10.1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05413850 ↗ |
| Known as | LUTETIUM (177LU) TEZUVOTIDE TETRAXETAN | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068768 ↗ |
| Known as | Lutetium Lu 177 PSMA-10.1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06105918 ↗ |
| Known as | Rhpsma-10.1 lutetium lu-177 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068768 ↗ |
| Modality | Other / unclassified | “the radiohybrid (177)Lu-rhPSMA-10.1” PMID 38164586 ↗ Mar 2024 |
| Route | Intravenous | “177Lu-rhPSMA-10.1 intravenously (IV) on study” NCT06105918 ↗ |